Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox!

Literature Review, February 2018

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

The effect of ethanolic extract of Thymus kotschyanus on cancer cell growth in vitro and depression-like behavior in the mouse. Doosti MH1, Ahmadi K1, Fasihi-Ramandi M1. J Tradit Complement Med. 2017 Apr 17;8(1):89-94. doi: 10.1016/j.jtcme.2017.03.003. eCollection 2018 Jan.

 

Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells. Jung CY1, Kim SY2, Lee C3. Anticancer Res. 2018 Jan;38(1):279-286.

 

Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Goncalves MD1,2,3, Hwang SK1,2, Pauli C4, et al. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752. doi: 10.1073/pnas.1714703115. Epub 2018 Jan 8.

SCREENING, DIAGNOISIS AND STAGING

An Assessment of Primary Care and Pulmonary Provider Perspectives on Lung Cancer Screening.

Triplette M1, Kross EK1, Mann BA2, Elmore JG1, Slatore CG3,4, Shahrir S1, Romine PE1, Frederick PD1, Crothers K1. Ann Am Thorac Soc. 2018 Jan;15(1):69-75. doi: 10.1513/AnnalsATS.201705-392OC.

 

Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.

Sato S1, Nagahashi M2, Koike T1, et al. Sci Rep. 2018 Jan 17;8(1):1005. Doi: 10.1038/s41598-017-18560-y.

 

Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration.

Joseph AM1, Rothman AJ2, Almirall D3, et al. Am J Respir Crit Care Med. 2018 Jan 15;197(2):172-182. doi: 10.1164/rccm.201705-0909CI.

 

Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent. Smeltzer MP1, Faris NR2, Ray MA1, Osarogiagbon RU2. JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.

 

EBUS: Faster, cheaper and most effective in lung cancer staging. Sampsonas F1, Kakoullis L1, Lykouras D1, Karkoulias K1, Spiropoulos K1. Int J Clin Pract. 2018 Jan 3. doi: 10.1111/ijcp.13053. [Epub ahead of print]

 

Improving the Implementation of Lung Cancer Screening Guidelines at an Academic Primary Care Practice. Brenner AT, Cubillos L, Birchard K, et al. J Healthc Qual. 2018 Jan/Feb;40(1):27-35. doi: 10.1097/JHQ.0000000000000089.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES - NSCLC SURGERY

Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.

Stokes WA1, Bronsert MR1, Meguid RA1, et al. J Clin Oncol. 2018 Jan 18:JCO2017756536. doi: 10.1200/JCO.2017.75.6536. [Epub ahead of print]

 

Left sleeve lobectomy versus left pneumonectomy for the management of patients with non-small cell lung cancer. Wang L1, Pei Y1, Li S1, Zhang S1, Yang Y1. Thorac Cancer. 2018 Jan 17. doi: 10.1111/1759-7714.12583. [Epub ahead of print]

 

A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making. Ye L1, Xu F2, Shi S1, Zeng Z1, Jin X3, Huang Y1, Lu C2, Gu J2, Ge D4, He J5. Clin Transl Oncol. 2018 Jan 11. doi: 10.1007/s12094-017-1819-7. [Epub ahead of print]

 

Outcomes after Video-assisted Thoracoscopic Lobectomy versus Open Lobectomy for Early-Stage Lung Cancer in Older Adults. Ezer N1, Kale M2, Sigel K2, et al. Ann Am Thorac Soc. 2018 Jan;15(1):76-82. doi: 10.1513/AnnalsATS.201612-980OC.

adults, even after controlling for surgeon experience.

 

Left sleeve lobectomy versus left pneumonectomy for the management of patients with non-small cell lung cancer. Wang L1, Pei Y1, Li S1, Zhang S1, Yang Y1. Thorac Cancer. 2018 Jan 17. doi: 10.1111/1759-7714.12583. [Epub ahead of print]

 

Significance of Body Mass Index for Postoperative Outcomes after Lung Cancer Surgery in Elderly Patients. Matsuoka K1, Yamada T2, Matsuoka T2, Nagai S2, Ueda M2, Miyamoto Y2. World J Surg. 2018 Jan;42(1):153-160. doi: 10.1007/s00268-017-4142-0.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES - NSCLC SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.

Frankel D1, Nanni-Metellus I2, Robaglia-Schlupp A1, et al. Clin Chem Lab Med. 2018 Jan 8. pii: /j/cclm.ahead-of-print/cclm-2017-0527/cclm-2017-0527.xml. doi: 10.1515/cclm-2017-0527. [Epub ahead of print]

 

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Hodi FS1, Ballinger M1, Lyons B1,et al. J Clin Oncol. 2018 Jan 17:JCO2017751644. doi: 10.1200/JCO.2017.75.1644. [Epub ahead of print]

 

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. DiBonaventura MD1, Wong W2, Shah-Manek B3,4, Schulz M2. Onco Targets Ther. 2017 Dec 22;11:75-82. doi: 10.2147/OTT.S144960. eCollection 2018.

 

Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer. Kataoka Y1, Hirano K2, Narabayashi T3, Hara S4, Fujimoto D5, Tanaka T6, Ebi N7, Tomii K5, Yoshioka H8. Anticancer Res. 2018 Jan;38(1):559-563.

 

Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Goncalves MD1, Taylor S2, Halpenny DF3, et al. Clin Radiol. 2018 Jan 6. pii: S0009-9260(17)30568-8. doi: 10.1016/j.crad.2017.12.004. [Epub ahead of print]

 

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. Oshima Y1, Tanimoto T2, Yuji K1, Tojo A1. JAMA Oncol. 2018 Jan 11. doi: 10.1001/jamaoncol.2017.4526. [Epub ahead of print]

 

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. McCall NS1, Dicker AP2, Lu B3. Clin Cancer Res. 2018 Jan 22. pii: clincanres.3269.2017. doi: 10.1158/1078-0432.CCR-17-3269. [Epub ahead of print]

 

Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Tao H1, Meng Q1, Li M1, Shi L1, Tang J1, Liu Z1. Thorac Cancer. 2018 Jan 3. doi: 10.1111/1759-7714.12582. [Epub ahead of print]

 

Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis. Hong J1, Liao Z1, Zhuang Y1, Levy LB1, Sheu T1, Heymach JV2, Nguyen QN1, Xu T1, Komaki R1, Gomez DR1. Am J Clin Oncol. 2018 Jan;41(1):46-52. doi: 10.1097/COC.0000000000000235.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES - NSCLC RADIOTHERAPY

Volumetric modulated arc therapy treatment planning of thoracic vertebral metastases using stereotactic body radiotherapy. Mallory M1, Pokhrel D2, Badkul R1, Jiang H1, Lominska C1, Wang F1. J Appl Clin Med Phys. 2018 Jan 19. doi: 10.1002/acm2.12252. [Epub ahead of print]

 

Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. Kocher MR, Sharma A, Garrett-Mayer E, Ravenel JG. J Comput Assist Tomogr. 2018 Jan/Feb;42(1):146-150. doi: 10.1097/RCT.0000000000000653.

 

The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer. Precival C1, Landy M1, Poole C1, Mullaney L2. Anticancer Res. 2018 Jan;38(1):7-14.

 

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Iyengar P1, Wardak Z1, Gerber DE2, et al. JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11.

 

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Tsao MN1, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A, Rakovitch E, Chow E. Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869. doi: 10.1002/14651858.CD003869.pub4. [Epub ahead of print]

 

Differences in lung injury after IMRT or proton therapy assessed by 18FDG PET imaging.

Shusharina N1, Liao Z2, Mohan R3, Liu A3, Niemierko A1, Choi N1, Bortfeld T1. Radiother Oncol. 2018 Jan 15. pii: S0167-8140(18)30012-4. doi: 10.1016/j.radonc.2017.12.027. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Barriers to Combined-Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Pezzi TA1, Schwartz DL1,2, Mohamed ASR1,3, et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4504. [Epub ahead of print]

deficiencies, and causative factors leading to heterogeneous care delivery.

 

Target engagement imaging of PARP inhibitors in small-cell lung cancer. Carney B1,2, Kossatz S1, Lok BH3,4, et al. Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

 

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions. Ohara S1,2, Kanda S1, Okuma H1, et al. Jpn J Clin Oncol. 2018 Jan 1;48(1):82-88. doi: 10.1093/jjco/hyx153.

PALLIATIVE AND SUPPORTIVE CARE

Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients.

Grotmol KS1, Lie HC2, Loge JH1, Aass N3, Haugen DF4, Stone PC5, Kaasa S6, Hjermstad MJ1. Palliat Support Care. 2018 Jan 10:1-7. doi: 10.1017/S1478951517001183. [Epub ahead of print]

 

Differential effects of early palliative care based on the age and sex of patients with advanced cancer from a randomized controlled trial. Nipp RD1, El-Jawahri A1, Traeger L2, Jacobs JM2, Gallagher ER1, Park ER2, Jackson VA3, Pirl WF4, Temel JS1, Greer JA2. Palliat Med. 2018 Jan 1:269216317751893. doi: 10.1177/0269216317751893. [Epub ahead of print]

 

Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. Awada G1, Klastersky J2. Curr Opin Oncol. 2018 Jan 4. doi: 10.1097/CCO.0000000000000434. [Epub ahead of print]

 

Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and their Family Caregivers. Winger JG1, Rand KL2, Hanna N3, et al. J Pain Symptom Manage. 2018 Jan 20. pii: S0885-3924(18)30012-5. doi: 10.1016/j.jpainsymman.2018.01.005. [Epub ahead of print]

 

Perspectives of newly diagnosed advanced cancer patients receiving dignity therapy during cancer treatment. Dose AM1, Rhudy LM2. Support Care Cancer. 2018 Jan;26(1):187-195. doi: 10.1007/s00520-017-3833-2. Epub 2017 Jul 21.

 

Intensity of Anxiety and Depression in Patients with Lung Cancer in Relation to Quality of Life.

Polański J1, Chabowski M2,3, Chudiak A4, Uchmanowicz B4, Janczak D5, Rosińczuk J6, Mazur G7. Adv Exp Med Biol. 2018;1023:29-36. doi: 10.1007/5584_2017_50.

useful predictive factor in lung cancer patients.

 

Shared Attributes of Responsibility and Emotion in Patients With Lung Cancer and Family Caregivers O’Rourke DJ1, Lobchuk MM, Ahmed R2. Oncol Nurs Forum. 2018 Jan 1;45(1):33-44. doi: 10.1188/18.ONF.33-44.

important for understanding emotional responses and determining interventions.

 

Proxy and patient reports of health-related quality of life in a national cancer survey. Roydhouse JK1, Gutman R2, Keating NL3, Mor V4, Wilson IB4. Health Qual Life Outcomes. 2018 Jan 5;16(1):6. doi: 10.1186/s12955-017-0823-5.

 

Cancer-associated cachexia. Baracos VE1, Martin L2, Korc M3, Guttridge DC4, Fearon KCH5. Nat Rev Dis Primers. 2018 Jan 18;4:17105. doi: 10.1038/nrdp.2017.105.

 

Evidence, education and multi-disciplinary integration are needed to embed exercise into lung cancer clinical care: A qualitative study involving physiotherapists. Granger CL1,2,3, Parry SM1, Denehy L1,3, Remedios L1. Physiother Theory Pract. 2018 Jan 16:1-9. doi: 10.1080/09593985.2018.1425939. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Cinnamomum Cassia Extracts Suppress Human Lung Cancer Cells Invasion by Reducing u-PA/MMP Expression through the FAK to ERK Pathways. Wu HC1, Horng CT2,3, Lee YL1, et al. Int J Med Sci. 2018 Jan 1;15(2):115-123. doi: 10.7150/ijms.22293. eCollection 2018.

MISCELLANEOUS WORKS

Smoking status and survival among a national cohort of lung and colorectal cancer patients.

Japuntich SJ1, Kumar P2, Pendergast J3, et al. Nicotine Tob Res. 2018 Jan 17. doi: 10.1093/ntr/nty012. [Epub ahead of print]

 

Health care disparities among octogenarians and nonagenarians with stage III lung cancer.

Cassidy RJ1, Zhang X2, Switchenko JM2, et al. Cancer. 2018 Jan 8. doi: 10.1002/cncr.31077. [Epub ahead of print]

 

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Lindeman NI1, Cagle PT1, Aisner DL1, et al. Arch Pathol Lab Med. 2018 Jan 22. doi: 10.5858/arpa.2017-0388-CP. [Epub ahead of print]

 

Not a Death Sentence: Perspectives of African American Women Living With Lung Cancer

Webb LA1, McDonnell KK1. Oncol Nurs Forum. 2018 Jan 1;45(1):46-54. doi: 10.1188/18.ONF.46-54.

Archives